LONDON, Jan. 31, 2025 /PRNewswire/ -- Accord Healthcare UK Ltd announces that following launch to wholesalers in Dec 2024, the alcohol deterrent compound Disulfiram (the active ingredient) will now be available to all UK pharmacists and dispensing doctors for prescription to suitable patients.

Disulfiram may be indicated as an adjuvant in the treatment of carefully selected and co-operative patients with drinking problems. Its use must be accompanied by appropriate supportive treatment.

When alcohol is consumed, it is metabolised in the body into acetaldehyde. Disulfiram works by blocking the enzyme which breaks down acetaldehyde. This leads to an increased level of acetaldehyde in the blood causing a number of unpleasant physical reactions including headache, heart palpitations and nausea. The experience of such reactions acts as a deterrent to the further consumption of alcohol.

Clara Carter, UK Country Manager, Generics says "At Accord we continually strive to 'make it better' by placing the patient at the centre, this new product launch underpins our commitment to the supply of generic medicines in the UK".

For clinical information, here is the link to the SmPC https://www.accord-healthcare-products.co.uk/products/d/disulfiram

Logo :

View original content:https://www.prnewswire.co.uk/news-releases/accord-healthcare-launches-disulfiram-in-the-united-kingdom-indicated-as-a-supportive-agent-in-the-treatment-of-alcoholism-302365306.html

Images

Tags

More Like This

Accord Healthcare unlocks £50m government fund to boost medicines manufacturing in the North-East

Innovative Remote Alcohol Treatment Service Launches to Help Isolated UK Communities

Accord Healthcare launches Accord Animal Health

Accord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara®

AHF Urges Trinidad and Tobago to Sidestep Greedy GSK

Clairvoyant Surpasses 50 Per Cent Randomization in its Phase 2b Psilocybin Therapy Trial for Alcohol Use Disorder

Accord Healthcare receives positive CHMP opinion for IMULDOSA®, a ustekinumab biosimilar to Stelara®

Alzheimer's Association Commends United Kingdom's Approval of Leqembi, But Condemns Decision to Deny NHS Access